Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan re-infusions in severe heart failure with reduced ejection fraction
2020-005893-93Phase 4Terminated
- Sponsor
- University of Białystok
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and heart failure (HF) comparing Levosimendan re-infusion with Placebo (2 arms). Primary endpoint: Composite of death or unplanned hospitalization due to heart failure. Started Jan 2021; status: terminated.
02
Drugs
levosimendan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure (HF)
Beyond the preview
Go deeper on 2020-005893-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005893-93.